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The Challenge
The HIV/AIDS pandemic continues to
spread and an AIDS vaccine is urgently
needed. While facing unprecedented chal-
lenges, AIDS vaccine development activi-
ties are continuing around the globe [1,2].
Recent results of the Thai Phase III vaccine
trial are renewing such efforts [3]. In
accordance with the goals of the Global
HIV Vaccine Enterprise (the Enterprise)
[4], there is now clear recognition of the
role that regional alliances can play in
fostering and facilitating AIDS vaccine
development [5], and there is broad
agreement that international collaborations
are the most effective way forward to
develop and evaluate the next generation
of AIDS vaccine candidates [6].
In response to these challenges, the
Asian region has recently formed the
AIDS Vaccine for Asia Network (AVAN),
with a clear vision and mission (Box 1).
The Need for AVAN: The HIV
Epidemic in the Asian Region
The total Asia population is approxi-
mately 4 billion people—just over 60% of
the world population. More than 500
million people are considered to be at-risk
for HIV exposure and infection, including
youth, injecting drug users (IDUs), sex
workers, men who have sex with men
(MSM), and mobile populations. Close to
5 million people have already been
infected with HIV across the region,
although the epidemic is highly variable
across different countries, communities
and populations [7].
Asian HIV sub-epidemics are driven
primarily by unsafe sex and drug injection
and are therefore currently concentrated
in groups with higher risk for HIV;
however, the epidemic is slowly spreading
into the general population. Although
impressive results have been achieved
following the scaling up of available HIV
prevention strategies in some countries
[8], the level of prevention, care, and
treatment coverage among risk-associated
groups remains unacceptably low.
The main factors influencing HIV
vaccine development in the region include
circulation of multiple HIV subtypes and
circulating recombinant forms (CRFs)
transmitted through the various modes of
transmission, diverse host genetics, and
disparate social, cultural, and political
contexts in the region. While IDUs were
the initial driving force of many HIV
epidemics in Asian countries, sexual trans-
mission has gradually taken over. Signifi-
cant increases in the number of new HIV
infections are also expected to occur across
the region among MSM. The geographic
distribution of HIV subtypes and CRFs is
relatively homogeneous but varies by
subcontinent: CRF_07B9/C, B9, and
CRF01_AE in China [9–11]; subtype C
in India [12]; and CRF01_AE in Thailand
[13] (Figure 1). Unfortunately, HIV inci-
dence data remain incomplete and need to
be bolstered for optimal planning of
vaccine studies. These interrelated factors
may affect AIDS vaccine research and
development in the region and therefore
should be given due consideration in
planning future studies. The complexity
of the epidemic in the region poses
substantial challenges but also affords
tremendous opportunities to accelerate
AIDS vaccine development considering
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epidemiology study in the region.
Current Efforts in HIV Vaccine
Research and Development in
Asia
Significant basic and clinical HIV
vaccine research and development efforts
are already underway across the region,
with notable achievements (see Table 1).
Several Asian countries now have Nation-
al AIDS Vaccine Plans and Strategies.
Further harmonization and consolidation
of efforts will result in more productive
associations and acceleration of AIDS
vaccine development.
Thailand
AIDS vaccine activities have a long-
standing history in Thailand, beginning in
the mid-1990s [14], reflecting a strong
political will to invest in AIDS vaccine
research and development to stem the
epidemic in Thailand. Thailand has con-
ducted Phase I, II, and III trials with the
AIDSVax gp120 B9/E vaccine, as well as
studiesofothercandidatevaccines(Table1).
Most notably, Phase III trials of the
ALVAC (Canarypox, vCP1521) and
AIDSVAX gp120 B/E prime-boost regi-
mens have also been completed. This
landmark trial, the largest AIDS vaccine
efficacy trial conducted to date involving
over 16,000 volunteers, showed a modest
(31%) but significant reduction in new
HIV infections and is the first time that an
AIDS vaccine has exhibited protection
against HIV acquisition [3].
The Thai experience in successfully
conducting two Phase III efficacy trials
has provided world-class expertise in
collaborative teamwork, community en-
gagement activities, good clinical practice,
ethical compliance, sample repositories,
immunology studies, good laboratory
practices, volunteer retention strategies,
and large-scale data management ap-
proaches. These efforts and investments
resulted in an extraordinary volunteer
retention rate of 96% during the latest
Phase III trial. The Thai experience offers
a good example of what can be achieved
through international collaboration. In
addition, several preclinical studies with
promising HIV vaccine candidates are
now ongoing in Thailand. Researchers in
Chulalongkorn University are working on
a HIV-1 AE/B mosaic DNA vaccine as
well as techniques to improve vaccine
delivery system. The Thailand Regional
Laboratories in the Comprehensive Anti-
body-Vaccine Immune Monitoring Con-
sortium are working with researchers from
the Los Alamos National Library and the
National Cancer Institute on a cocktail of
the mosaic DNA vaccine and DNA/
vaccinia primed-boosted strategy. These
candidates were tested in mice and have
shown a promising immunogenicity result.
China
The Chinesegovernmenthassignificantly
invested in AIDS vaccine research. China’s
vaccine scientists have recently formed the
Chinese AIDS Vaccine Initiative (CAVI),
supported by the government of China. The
initiative includes projects aimed at cohort
development, vaccine vector design, estab-
lishment of clinical trial units, a manufac-
turing facility using principles of good
manufacturing practice (GMP), a primate
centre, a humanized mouse centre, and
technical platforms encompassing both neu-
tralizing antibody and T cell expertise.
Clinical studies conducted so far include
three Phase I trials: V3 peptide vaccine in
1993, DNA/MVA (modified vaccinia
Ankara) in 2005, and a DNA/Tiantan
vaccinia strain (replication-competent) in
2007 (Table 1). Pre-clinical studies with
DNA and modified Tiantan vaccinia, as
Summary Points
N The HIV/AIDS pandemic continues to spread and an AIDS vaccine is urgently
needed.
N Regional alliances and international collaborations can foster the development
and evaluation of the next generation of AIDS vaccine candidates.
N The importance of coordinating and harmonizing efforts across regional
alliances has become abundantly clear.
N We recently formed the AIDS Vaccine for Asia Network (AVAN) to help facilitate
the development of a regional AIDS vaccine strategy that accelerates research
and development of an AIDS vaccine through government advocacy, improved
coordination, and harmonization of research; develops clinical trial and
manufacturing capacity; supports ethical and regulatory frameworks; and
ensures community participation.
Box 1. AVAN’s Vision and Mission
Vision
N To develop a safe and effective AIDS vaccine and ensure its access as a part of a
comprehensive public health strategy for the control of new HIV infections
across the Asian region.
Goals
N To accelerate the development of an AIDS vaccine through expanding capacity
for all aspects of AIDS vaccine research and development.
N To build up regional resource centres and collaborative platforms to promote
innovative AIDS vaccine research strategies.
N To enlarge the pipeline of candidate AIDS vaccines suitable for use among
Asian populations.
N To strengthen capacity and harmonize regulatory and ethical frameworks for
the conduct of clinical trials that comply with internationally recognized
standards.
N To actively involve community partners at all stages of AIDS vaccine
development, clinical trials, and future use.
N To promote and share manufacturing and production capacity in the region, in
compliance with GMP standards, both for clinical trials and for the potential of
high demand for an AIDS vaccine in Asia.
N To engage with and advocate to governments and the private sector to commit
to and provide political and financial support for all phases of AIDS vaccine
research and development, including licensing and future access.
N To facilitate collaboration between Asian scientists and industry with the rest of
the world.
N To align with the values and strategic goals of the Global HIV Vaccine
Enterprise.
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and adenovirus vector approaches for
inducing mucosal immunity show consid-
erable promise [15–17]. China’s AIDS
vaccine programme now has substantial
capacity in primate centres, vaccine pro-
duction, and clinical trial sites develop-
ment that will all help to facilitate further
research and development in the region.
India
AIDS vaccine trials have accelerated
significantly in India in recent years.
Activities include an adeno-associated
virus vector Phase I trial, modified MVA
vector vaccine trials [18,19], and a recent
DNA/MVA Phase I prime-boost trial
initiated in 2009 [20]. The International
AIDS Vaccine Initiative (IAVI) is support-
ing Indian AIDS vaccine trials and applied
research on neutralizing antibody immu-
nogens [21]. Exploration of several novel
concepts, including prime-boost regimens
with CD40L adjuvants, as well as research
towards development of improved Env-
based immunogens, is also progressing.
Improved awareness of AIDS vaccine
issues, training of staff, and development
Figure 1. Regional distribution of HIV-1 subtypes and recombinants. The relative proportion of each subtype/recombinant is shown in the
pie chart for each country. The data on Figure 1 are from the former studies in the region and estimates made by AVAN Task Force members of the
manuscript based on the unpublished data of their own research projects.
doi:10.1371/journal.pmed.1000331.g001
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the capacity of conducting AIDS vaccine
research and clinical trials within India.
Australia
Australia has long-standing capacities in
both fundamental HIV research and
clinical trial activities. A consortium,
termed the Australia-Thai HIV Vaccine
Consortium, conducted two recent trials,
first in Sydney and then in Bangkok, of a
DNA-prime and Fowlpox virus boost
vaccine using both subtype B and
CRF01_AE strains [22]. Australia was a
clinical trial site of the adenovirus-based
efficacy (STEP) trial that was not effica-
cious. Through collaborations, several new
vaccine candidates are emerging. These
include peptide-based vaccines, gp140
immunogens, recombinant influenza vec-
tors, and particle-based vaccine strategies
[23,24]. In addition, improved and sim-
pler assays to measure T cell immunity
and antibody-dependent cellular cytotox-
icity (ADCC) are emerging [25,26]. These
scientific approaches could be accelerated
into expanded clinical trials in future
collaborations across the Asian region.
Japan
Japan has developed a pipeline of
promising AIDS vaccine candidates.
These include recombinant Mycobacterium
bovis/Bacillus Calmette-Gue ´rin (BCG)
vector-based regimens that are moving
towards clinical trial development in
collaboration with Thai groups [27]. In
addition, novel Sendai virus vectors are
being developed with the opportunity to
deliver vaccines mucosally to induce
mucosal immunity [28]. Sendai virus
vectors combined with DNA vaccine
candidates are moving towards clinical
trials in collaboration with IAVI.
The Evolution, Mission, and
Strategic Plan Development of
AVAN
The first Asian meetings devoted to
AIDS vaccines took place in Japan, China,
and Thailand in the late 1990s. The initial
efforts were followed by a World Health
Organization (WHO)/Joint United Na-
tions Programme on HIV/AIDS (UN-
AIDS) regional consultation on AIDS
vaccines in Japan in 2006 and in Beijing
in 2009 [29–31]. The challenges for
engaging countries and communities in
expanding pre-clinical and clinical trials,
and in enhancing regulatory and manu-
facturing capacity to accelerate the devel-
opment of AIDS vaccines in the region,
led to the establishment of AVAN, an-
nounced at the 2009 AIDS Vaccine
Conference in Paris. AVAN has had
regular consultations towards developing
an Asia-specific Strategic AIDS Vaccine
Plan in alignment with the Enterprise
Scientific Strategic Plan [6].
An AVAN Task Force was recently
established to foster further dialogue and
set the stage for the development of
principles and priorities for a focussed,
forward-looking and effective strategic
plan for the network. Eventually, the Task
Force will be replaced by a steering
committee to guide implementation of a
strategic plan. An initial AVAN Task
Force secretariat has been established,
currently based in China, with strong
support from the Chinese AIDS Vaccine
Initiative, WHO, the Enterprise, and the
Chinese government. The Task Force and
secretariat foster forums for consultation
and networking around many of the most
critical future issues. Regional workshops
are planned to further implement the
emerging strategic plan in June 2010 in
Bangkok, Thailand, and in August/Sep-
tember 2010 in Sapporo, Japan. AVAN
plans to support and promote the devel-
opment of regional resource centres to
provide information, a reagents repository,
protocols, and training on the many
aspects of AIDS vaccine research and
development. Coordination and harmoni-
zation of various aspects of AIDS vaccine
development, particularly regional vaccine
immunology evaluation laboratories and
regulatory reviews, is a high priority in
moving AIDS vaccine research forward
Table 1. AIDS Vaccine Trials across Asia to Date.
Country Vaccine Sponsor Subtype Phase/Time Reference
Thailand V3 peptides UBI Multiclade I/1994 [32]
gp120 Vaxgen, Chiron E, B, B9/E I/II,III/1995 [33]
gp160 DoD E I/II
Canarypox+gp 160 vs. gp 120 US NIH/DoD B/E I/II/2003 [34]
Adenovirus type 5 Merck B I/II/2003
MVA US NIH/DoD A/E I [35]
DNA+fowlpox Australia A/E I/2004 [36]
Canarypox+gp 120 US NIH/DoD B/E III/2006 [3]
China V3 peptides UBI Co. Multiclade I/1993 [31]
DNA+MVA Baike Co. CRF08_B/C I/2005
Tiantan vaccinia replicative China CDC/EU CRF 07_B/C I/2006 [15]
DNA+Tiantan replicative China CDC CRF 07_B/C I/2008 [37]
DNA+MVA Baike Co. CRF08_B/C II/2009
India Adeno-associated virus IAVI C I/2003 [18]
MVA IAVI C I/2005 [20]
AAV vs. DNA+MVA IAVI C I/2009 [38]
Australia DNA+fowlpox US NIH B I/2004 [21]
DNA+fowlpox Australia A/E I [36]
CDC, Center for Disease Control and Prevention; DoD, Department of Defense; EU, European Union.
doi:10.1371/journal.pmed.1000331.t001
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come the key advocate for AIDS vaccine
research in the region, building upon the
trust created through working together in
collaborative partnerships in the region
and with support from the Enterprise.
Past Collaborations and Future
Opportunities
AVAN aims to make a significant impact
as the region undertakes a stronger role in
AIDS vaccine research and development.
Asian investigators have substantial capac-
ity to conduct basic research, which could
be significantly enhanced through better
collaboration. The current pipeline of new
vaccine candidates needs further expansion
with more innovative concepts and trans-
national efforts to accelerate research.
Clinical trial capacity could be quickly
exhausted with multiple, concurrent effica-
cy trials in the future. As partially effica-
cious AIDS vaccines are identified either in
Asia oraroundtheworld,determiningtheir
effectiveness in regional epidemics involv-
ing differing HIV virus subtypes will be
critical. Considering the large number of
IDUs in many countries of the region still
with a high incidence of HIV infection,
Asia may serve as the ideal site suitable for
testing a vaccine to prevent parental HIV
transmission.
Building upon and maintaining the
substantial efficacy trials expertise in Thai-
land is both an opportunity and a
challenge. Substantial opportunities exist
to harmonize the regulatory and ethical
review of AIDS vaccine trials across the
region—too often, delays experienced in
initiating trials with vectors of known
safety profile are very lengthy. Data
management and data sharing across the
region can also be enhanced. Opportuni-
ties for training young immunologists and
virologists in the region to foster the next
generation of scientists need to be encour-
aged and supported. Technology transfer
from Western countries to Asian countries
also needs to be strengthened. Finally,
tapping into the large cost-effective vac-
cine manufacturing capacity in several
Asian countries is an opportunity and
priority.
International groups have previously
provided high level support for AIDS
vaccine activities in the Asian region,
including research and technical transfer,
funding and policy. In the past two
decades, the US National Institutes of
Health (NIH) has provided extensive
support for basic and clinical research
across many Asian countries and funded
the majority of the RV 144 trial. The
Walter Reed Army Institute of Research
and the US Military HIV Research
Program (MHRP), in collaboration with
the Royal Thai Army, sponsored several
clinical trials in Thailand, including the
RV144 trial. IAVI is supporting clinical
trial capacity building along with policy
and preparedness activities. The Euro-
Vacc AIDS Vaccine network has included
the Chinese HIV strains in their develop-
ment work in view of future plans of
conducting trials in the region. The
Collaboration for AIDS Vaccine Discov-
ery (CAVD), supported by the Bill &
Melinda Gates Foundation, is also looking
towards enhancing research on AIDS
vaccines in Asia in coming years. WHO-
UNAIDS and the Global HIV Vaccine
Enterprise are actively engaging in policy
development, assisting the development of
national AIDS vaccine plans, and provid-
ing a global umbrella for AIDS vaccine
development activities in Asia. Further
investment in AIDS vaccine development
by the most developed nations in the Asian
region would be welcome. The consolida-
tion of this collaborative support will be
critical in progressing future vaccine
development efforts.
Conclusions
The development of an effective AIDS
vaccine has never been more urgent,
particularly for the hundreds of millions
of people across Asia at substantial risk of
acquiring HIV. Similarly, the necessity of
coordinating and harmonizing efforts
across regional alliances has become
abundantly clear. AVAN has been initiat-
ed to meet these needs and actively
facilitate the development of a regional
AIDS vaccine strategy that accelerates
research and development of an AIDS
vaccine through government advocacy,
improved coordination and harmoniza-
tion of research; develops clinical trial and
manufacturing capacity; supports ethical
and regulatory frameworks; and ensures
community participation.
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